Attached files

file filename
10-K - 10-K - Sio Gene Therapies Inc.axovant3311810k.htm
EX-32.2 - EXHIBIT 32.2 - Sio Gene Therapies Inc.axovantexhibit322.htm
EX-32.1 - EXHIBIT 32.1 - Sio Gene Therapies Inc.axovantexhibit321.htm
EX-31.2 - EXHIBIT 31.2 - Sio Gene Therapies Inc.axovantexhibit312.htm
EX-31.1 - EXHIBIT 31.1 - Sio Gene Therapies Inc.axovantexhibit311.htm
EX-23.2 - EXHIBIT 23.2 - Sio Gene Therapies Inc.axovantexhibit232.htm
EX-21.1 - EXHIBIT 21.1 - Sio Gene Therapies Inc.axovantexhibit211.htm
EX-10.24 - EXHIBIT 10.24 - Sio Gene Therapies Inc.axovantexhib1024.htm
EX-10.23 - EXHIBIT 10.23 - Sio Gene Therapies Inc.axovantexhib1023.htm
EX-10.22 - EXHIBIT 10.22 - Sio Gene Therapies Inc.axovantexhib1022.htm
EX-10.21 - EXHIBIT 10.21 - Sio Gene Therapies Inc.axovantexhib1021.htm

Exhibit 23.1




CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements of Axovant Sciences Ltd.:

(1) Registration Statement (Form S-8 No. 333-206300) pertaining to the 2015 Equity Incentive Plan,
(2) Registration Statement (Form S-8 No. 333-215386) pertaining to the 2015 Equity Incentive Plan,
(3) Registration Statement (Form S-3 No. 333-215387), and
(4) Registration Statement (Form S-8 No. 333-220089) pertaining to the Amended and Restated 2015 Equity
Incentive Plan;
of our report dated June 11, 2018, with respect to the consolidated financial statements of Axovant Sciences Ltd. included in this Annual Report (Form 10-K) of Axovant Sciences Ltd. for the year ended March 31, 2018.  

/s/ Ernst & Young LLP
Iselin, New Jersey
June 11, 2018


1